Brevan Howard Capital Management LP Cullinan Oncology, Inc. Transaction History
Brevan Howard Capital Management LP
- $13.9 Billion
- Q4 2024
A detailed history of Brevan Howard Capital Management LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 14,735 shares of CGEM stock, worth $126,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,735Holding current value
$126,868% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
67.1MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$65.9 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.5 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.6 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.4 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$29.1 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $393M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...